Therapeutics was Cellectis’s largest revenue line in fiscal 2020, bringing in $51.06M of $73.95M (69%).
| Products and services [axis] | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|
| Therapeutics | $24.68M | $12.50M | $7.90M | $51.06M |
| Plants | $508.00K | $236.00K | $7.29M | $22.89M |
| Total | $25.19M | $12.73M | $15.19M | $73.95M |
Cellectis brought in $73.95M from its two revenue lines in fiscal 2020, the year ended December 31, 2020. That was up 386.8% from $15.19M in fiscal 2019. Therapeutics was the largest at $51.06M (69.0%), ahead of Plants at $22.89M (31.0%).
Compared with fiscal 2019, Therapeutics grew 546.6% to $51.06M and Plants grew 213.8% to $22.89M. From fiscal 2017 to 2020, combined revenue from these revenue lines grew from $25.19M to $73.95M, a compound annual growth rate of 43.2%. Therapeutics' share of the total fell from 98.0% to 69.0%.
Cellectis (CLLS) reports its revenue by products and services [axis]. In fiscal 2020, Therapeutics was its largest revenue line, bringing in $51.06M (69.0% of the total), followed by Plants at $22.89M (31.0%).
Therapeutics was Cellectis' largest revenue line in fiscal 2020, bringing in $51.06M, or 69.0% of the $73.95M total across its two revenue lines.
Therapeutics grew faster than Plants in fiscal 2020, up 546.6% from $7.90M to $51.06M. Plants grew 213.8% to $22.89M.
Every figure comes from Cellectis' annual financial filings, as reported. Each line keeps the name Cellectis gives it, and years follow its fiscal calendar.
Cellectis' revenue by products and services [axis] goes back to fiscal 2017, with figures through fiscal 2020. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.